|
|
| Product Name: | RGDV | | Synonyms: | RGDV;arginyl-glycyl-aspartyl-valine;ARG-GLY-ASP-VAL;H-ARG-GLY-ASP-VAL-OH;L-Valine, L-arginylglycyl-L-α-aspartyl- | | CAS: | 93674-99-8 | | MF: | C17H31N7O7 | | MW: | 445.47 | | EINECS: | | | Product Categories: | Peptide | | Mol File: | 93674-99-8.mol |  |
| Melting point | 120-121 °C | | density | 1.51±0.1 g/cm3(Predicted) | | storage temp. | -15°C | | pka | 3.19±0.10(Predicted) |
| Uses | RGDV is a platelet aggregation inhibitor. RGDV inhibits platelet-dependent thrombus formation. RGDV is used for tumor recognition via the targeting effect[1][2]. | | References | [1] Cadroy Y, et, al. RGDV peptide selectively inhibits platelet-dependent thrombus formation in vivo. Studies using a baboon model. J Clin Invest. 1989 Sep;84(3):939-44. DOI:10.1172/JCI114256 [2] Wang F, et, al. Preparation and biological evaluation of tumor-specific Ara-C liposomal preparations containing RGDV motif. J Pharm Sci. 2012 Dec;101(12):4559-68. DOI:10.1002/jps.23326 |
| | RGDV Preparation Products And Raw materials |
|